Przejdź do zawartości
Merck

Gonadotrophin-releasing hormone agonist triggering may improve central oocyte granularity and embryo quality.

Zygote (Cambridge, England) (2020-04-04)
Kuo-Chung Lan, Yu-Chen Chen, Yi-Chi Lin, Yi-Ru Tsai
ABSTRAKT

This study aimed to describe outcomes in four women aged 28-34 years with central cytoplasmic granulation (CCG) of the oocytes who underwent in vitro fertilization/intracytoplasmic sperm injection (ICSI) using gonadotrophin-releasing hormone (GnRH) agonist to replace human chorionic gonadotrophin (hCG) as a trigger of final oocyte maturation. The initial ICSI procedure showed that all four women had CCG of the ooplasm and poor quality embryos. Subsequent ICSI used an antagonist protocol with a GnRH agonist trigger replacing the agonist protocol, plus hCG triggered ovulation. Ooplasm and embryo quality were improved in all four patients. All four became pregnant and gave birth to live infants. This study provides GnRH agonist triggering that may improve ooplasm granularity and embryo quality.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Cetrorelix acetate, ≥98% (HPLC)
Sigma-Aldrich
Luteinizing hormone releasing hormone, ≥97% (HPLC)
Sigma-Aldrich
Hyaluronidase from bovine testes, Type VIII, lyophilized powder, 300-1,000 U/mg